Malignant peritoneal mesothelioma
MONDO:0005512An aggressive malignant mesothelioma that arises from the peritoneum. Patients usually present with abdominal pain and ascites.
Also known as: advanced malignant mesothelioma of peritoneum, advanced malignant mesothelioma of the peritoneum, advanced peritoneal malignant mesothelioma, diffuse malignant peritoneal mesothelioma, malignant mesothelioma (disease) of peritoneum, malignant peritoneal mesothelioma, advanced, peritoneal mesothelioma (disease), malignant, peritoneum malignant mesothelioma (disease)
2750 clinical trials for this condition and its sub-types, 13 tagged with Malignant peritoneal mesothelioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug could extend life for mesothelioma patients
Disease control OngoingThis phase 2b trial tests whether the immunotherapy drug tremelimumab can help people with advanced mesothelioma live longer. About 571 patients who have already tried standard chemotherapy will receive either tremelimumab or a placebo. The main goal is to see if the drug improve…
Phase 2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New combo therapy targets rare abdominal cancer
Disease control PausedThis study tests whether adding a special chemotherapy spray (PIPAC) directly into the abdomen to standard IV chemo can help people with a rare cancer of the belly lining (peritoneal mesothelioma) live longer. About 66 adults who have not had prior treatment will be randomly assi…
Phase 2 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC